Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
View Patent ↗Crystalline polymorphous forms of rifaximin (INN), referred to as rifaximin α and rifaximin β, and a poorly crystalline form referred to as rifaximin γ, useful in the production of medicaments containing rifaximin for oral and topical use and obtained by means of a crystallization process carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a fixed temperature and for a fixed period of time, followed by a drying under controlled conditions until reaching a precise water content in the end product, are the object of the invention.
1. A pharmaceutical composition comprising a polymorphic form of rifaximin together with a pharmaceutically acceptable carrier, wherein the polymorphic form is form α, having x-ray powder diffraction pattern peaks at about:
7.4°, 7.9°, and 11.8°; or
7.4°, 8.8°, and 11.8°; or
7.4°, 10.5°, and 11.8°; or
7.4°, 11.1°, and 11.8°; or
7.4°, 11.8° and 12.9°; or
7.4°, 11.8° and 17.6°; or
7.4°, 11.8° and 19.7°; or
7.4°, 11.8° and 21.4°; or
7.4°, 11.8° and 22.1°, or
7.4°,11.1°, and 12.9°; or
7.4°, 11.1°, and 19.7°; or
7.4°, 12.9°, and 19.7°; or
11.1°, 11.8°, and 19.7°; or
11.1°, 19.7°, and 21.4°; or
11.1°, 19.7°, and 22.1°, or
11.8°, 12.9°, and 19.7°; or
11.8°, 19.9°, and 22.1°, 2θ.
2. The pharmaceutical composition of claim 1 , wherein after administration of the pharmaceutical composition to a patient, an observed plasma concentration of rifaximin in the patient is negligible.
3. The pharmaceutical composition of claim 1 , wherein the composition further comprises an excipient.
4. The pharmaceutical composition of claim 2 , wherein the excipient is selected from the group consisting of a diluting agent, a binding agent, a lubricating agent, a disintegrating agent, a coloring agent, a flavoring agent, and a sweetening agent.
5. The pharmaceutical composition of claim 2 , wherein the composition is for oral use and is in a form selected from the group consisting of coated or uncoated tablets, hard or soft gelatin capsules, sugar-coated pills, lozenges, wafer sheets, pellets, and powders in sealed packet.
6. The pharmaceutical composition of claim 2 , wherein the composition comprises one or more of colloidal silicon dioxide, hydroxypropyl methylcellulose, cellulose, microcrystalline cellulose, propylene glycol, sodium starch glycolate.
7. A pharmaceutical composition comprising a polymorphic form of rifaximin together with a pharmaceutically acceptable carrier, wherein the polymorphic form is form β, having x-ray powder diffraction pattern peaks at about:
5.4°, 6.4°, and 7.0°, or
5.4°, 6.4°, and 7.8°; or
5.4°, 6.4°, and 9.0°; or
5.4°, 6.4°, and 10.4°; or
5.4°, 6.4°, and 13.1°, or
5.4° and 7.0°, and 14.4°; or
5.4°, 10.4°, and 18.3°; or
5.4°, 10.4°, and 20.9°; or
5.4°, 10.4°, and 17.1°, or
6.4°, 7.0°, and 10.4°; or
6.4°, 7.8° and 10.4°; or
6.4°, 9.0° and 10.4°; or
6.4°, 10.4°, and 14.4°; or
10.4°, 13.1°, and 14.4°; or
10.4°, 17.1°, and 17.9°; or
10.4°, 17.9°, and 18.3°; or
10.4°, 17.9°, and 20.9°; or
10.4°, 18.3°, and 20.9°; or
14.4°, 17.1°, and 18.3°; or
17.1°, 18.3°, and 20.9°; or
14.4°, 17.1°, and 20.9°, 2θ.
8. The pharmaceutical composition of claim 7 , wherein after administration of the pharmaceutical composition to a patient, an observed plasma concentration of rifaximin in the patient is negligible.
9. The pharmaceutical composition of claim 7 , further comprising an excipient.
10. The pharmaceutical composition of claim 9 , wherein the excipient is selected from the group consisting of a diluting agent, a binding agent, a lubricating agent, a disintegrating agent, a coloring agent, a flavoring agent, and a sweetening agent.
11. The pharmaceutical composition of claim 7 , wherein the composition is for oral use and is in a form selected from the group consisting of coated or uncoated tablets, hard or soft gelatin capsules, sugar-coated pills, lozenges, wafer sheets, pellets, and powders in sealed packet.
12. The pharmaceutical composition of claim 10 , wherein the composition comprises one or more of colloidal silicon dioxide, hydroxypropyl methylcellulose, cellulose, microcrystalline cellulose, propylene glycol, sodium starch glycolate.
13. A pharmaceutical composition comprising a polymorphic form of rifaximin together with a pharmaceutically acceptable carrier, wherein the polymorphic form is form γ, having x-ray powder diffraction pattern peaks at about 5.0°, 7.1°, and 8.4° 2θ and an intrinsic dissolution rate of about 0.14 mg/min/cm 2 .
14. The pharmaceutical composition of claim 13 , wherein after administration of the pharmaceutical composition to a patient, an observed plasma concentration of rifaximin is of about 670 ng/ml.
15. The pharmaceutical composition of claim 14 , wherein the composition further comprises an excipient.
16. The pharmaceutical composition of claim 15 , wherein the excipient is selected from the group consisting of a diluting agent, a binding agent, a lubricating agent, a disintegrating agent, a coloring agent, a flavoring agent, and a sweetening agent.
17. The pharmaceutical composition of claim 14 , wherein the composition is for oral use and is in a form selected from the group consisting of coated or uncoated tablets, hard or soft gelatin capsules, sugar-coated pills, lozenges, wafer sheets, pellets, and powders in sealed packet.
18. The pharmaceutical composition of claim 16 , wherein the composition comprises one or more of colloidal silicon dioxide, hydroxypropyl methylcellulose, cellulose, microcrystalline cellulose, propylene glycol, sodium starch glycolate.